Related Experiment Video
Updated: Aug 15, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Aroma-Platins: A Modular Extended-Aromatic β-Diketonate Platinum(II) Platform for Tunable Activation and Anticancer
Megha Biswas1, Kanishka Chaudhary1, Kajol1,2
1Department of Chemical Sciences, Indian Institute of Science Education and Research Berhampur, Laudigam, Konisi, District Ganjam, Berhampur, Odisha, India.
None:
Platinum chemotherapy is often limited by nonspecific reactivity and variable intracellular activation. Here, we introduce Aroma-Platins, a rationally designed series of Pt(II) β-diketonate prodrug-like complexes in which the extended aromatic ring size of the β-diketonate leaving group is increased to program activation behavior and biological performance. Three congeners (Phn-Platin, Nap-Platin, and Ant-Platin) were synthesized and fully characterized, enabling a direct structure-property analysis across the series. Time-resolved studies under physiological conditions revealed ring-size-dependent activatability, with faster ligand release/complex transformation for larger π-surfaces. This reactivity was further enhanced in the presence of glutathione and dGMP, consistent with intracellular cues relevant to platinum pharmacology. Biomolecular interaction studies using ctDNA showed progressively stronger DNA association, most pronounced for Ant-Platin. In vitro evaluation across two aggressive cancer models, MDA-MB-468 and MiaPaCa2, demonstrated that Aroma-Platins are markedly more cytotoxic than their free ligands and carboplatin, with live/dead staining corroborating enhanced cell killing. Ant-Platin also exhibited enhanced DNA damage, as evidenced by immunofluorescence and cell cycle analysis studies in MDA-MB-468 cells. Collectively, this work establishes leaving-group π-engineering as a practical handle to tune Pt(II) prodrug activation, uptake, and efficacy, identifying Ant-Platin as a lead candidate for formulation-enabled translational and preclinical development.
Related Concept Videos
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3
Aromatic Hydrocarbon Cations: Structural Overview
Removing one hydrogen from the intervening CH2 group with both...
Cycloaddition Reactions: MO Requirements for Thermal Activation
ortho–para-Directing Deactivators: Halogens
Reduction of Alkenes: Asymmetric Catalytic Hydrogenation
The metal catalyst used can be either heterogeneous or homogeneous. When hydrogenation of an alkene generates a chiral center, a pair of enantiomeric products is expected to form. However, an enantiomeric excess of one of the products can be facilitated using an enantioselective reaction or an...

